Implications of cancer evolution for drug development

被引：27

作者：

Turajlic, Samra ^{[1
,2
,3
]}

Swanton, Charles ^{[1
,4
]}

机构：

[1] Francis Crick Inst, Translat Canc Therapeut Lab, 1 Midland Rd, London NW1 1AT, England

[2] Royal Marsden Hosp, Renal Unit, London SW3 6JJ, England

[3] Royal Marsden Hosp, Skin Unit, London SW3 6JJ, England

[4] UCL, Canc Res UK Lung Canc Ctr Excellence, Canc Inst, Paul OGorman Bldg,72 Huntley St, London WC1E 6BT, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2017年 / 16卷 / 07期

关键词：

HETEROGENEITY; RESISTANCE;

D O I：

10.1038/nrd.2017.78

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance.

引用

页码：441 / 442

页数：2

共 50 条

[21] LEUKOTRIENES IN DISEASE IMPLICATIONS FOR DRUG DEVELOPMENT
HIGGS, GA
MONCADA, S
DRUGS, 1985, 30 (01) : 1 - 5
[22] Ethnic diversity: Implications for drug development
Gross, Annette S.
DRUG METABOLISM REVIEWS, 2006, 38 : 30 - 31
[23] CAST - IMPLICATIONS FOR DRUG DEVELOPMENT - COMMENTARY
WOOSLEY, RL
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) : 553 - 556
[24] EVOLUTION OF THEORETICAL METHODS IN DRUG DEVELOPMENT
HANSCH, C
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1986, 192 : 19 - HIST
[25] The evolution of antiepileptic drug development and regulation
Arzimanoglou, Alexis
Ben-Menachem, Elinor
Cramer, Joyce
Glauser, Tracy
Seeruthun, Rav
Harrison, Miranda
EPILEPTIC DISORDERS, 2010, 12 (01) : 3 - 15
[26] THE NEWEST STAGE IN THE EVOLUTION OF DRUG DEVELOPMENT
Ross, Jeffrey S.
DRUG NEWS & PERSPECTIVES, 2009, 22 (01) : 59 - 59
[27] Evolution and intelligent design in drug development
Agafonov, Roman V.
Wilson, Christopher
Kern, Dorothee
FRONTIERS IN MOLECULAR BIOSCIENCES, 2015, 2
[28] In vitro evolution of proteins for drug development
Delagrave, S
Murphy, DJ
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2003, 1 (01) : 187 - 198
[29] DEREGULATION OF THE AKT-RELATED PATHWAY IN CANCER: IMPLICATIONS FOR RESISTANCE TO THERAPY AND DRUG DEVELOPMENT
Romano, G.
DRUGS OF THE FUTURE, 2013, 38 (01) : 37 - 42
[30] Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development
Zhang, Yanxia
Xiao, Bin
Liu, Yunduo
Wu, Shunhong
Xiang, Qin
Xiao, Yuhan
Zhao, Junxiu
Yuan, Ruanfei
Xie, Keping
Li, Linhai
EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 964

← 1 2 3 4 5 →